Zydus to Enter Global Biologics CDMO Business Plans to Acquire Agenus' U.S. Manufacturing Facilities to Accelerate Development of Innovative Therapies
Jun 03, 2025
New Jersey [US]/ Ahmedabad (Gujarat) [India], June 3: Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as "Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer.
Read More...
